• News
  • SAN DIEGO
  • BioTech

Isis begins study for cardiovascular disease treatment

Carlsbad-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has initiated a Phase 1 clinical study for an anti-sense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease.

ISIS-ANGPTL3Rx is designed to act as a broad dyslipidemia agent and has the potential to reduce LDL-cholesterol and triglycerides, to increase insulin sensitivity.

Isis plans to evaluate ISIS-ANGPTL3Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease.

The Phase 1 study of ISIS-ANGPTL3Rx is a blind, placebo-controlled, dose-escalation study in approximately 48 healthy volunteers. The study is designed to assess the safety, tolerability and pharmacokinetics of both single and multiple doses of ISIS-ANGTPL3Rx.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
44.62
  0.68  
+ 1.55%
1,703,078,000
77.8
37.38

Insider Trade Data

Date Insider Shares Type Value
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
07/06/2015 Crooke, Stanley T 12,350 Sell $707,457

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
Subscribe Today!